The Lynx Group
Cholangiocarcinoma News

Emerging Therapies

June/July 2021, Vol 2, No 2 — July 28, 2021
The FDA granted accelerated approval to the kinase inhibitor infigratinib (Truseltiq) for the treatment of adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma (CCA) that harbors an FGFR2 fusion or other rearrangement.
Read More

June/July 2021, Vol 2, No 2 — July 28, 2021
The primary results of the phase 2 FOENIX-CCA2 clinical trial of futibatinib in patients with previously treated intrahepatic cholangiocarcinoma (CCA) and FGFR2 fusions or rearrangements were presented by Lipika Goyal, MD, MPhil, Assistant Professor of Medicine, Massachusetts General Hospital, Boston, at the 2021 Annual Meeting of the American Association for Cancer Research (AACR).
Read More

March 2021, Vol 2, No 1 — April 13, 2021
In February 2021, Basilea Pharmaceuticals reported early results from the phase 2 FIDES-01 clinical trial (NCT03230318), which is evaluating the efficacy of derazantinib, an investigational small-molecule FGFR1-3 inhibitor, in patients with inoperable or advanced intrahepatic cholangiocarcinoma (CCA) and FGFR2 gene fusions or FGFR2 gene mutations or amplifications. Derazantinib also inhibits the colony-stimulating factor 1 receptor kinase (CSF1R). CSF1R-mediated signaling is important for the maintenance of tumor-promoting macrophages.
Read More

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to receive the free CCA News print publication or weekly e‑Newsletter.

I'd like to receive: